Trading above analyst consensus PT of $75. Secular catalysts (nuclear, HFO, AI chips) compelling but largely priced in at ~30x forward earnings. Maintain HOLD into Q1 2026 results — margin recovery is the key test.
Next catalystLoading earnings calendar…—
Segment mix — FY2025 revenue
Refrigerants & Applied Solutions (RAS)
72% · $2,793M FY2025
Refrigerants · Nuclear UF6 · Building Solutions · Aclar Packaging
~$90–100Q1 2026 results confirm margin recovery — EBITDA margin prints at or above 25%, validating management guidance. Commercial refrigeration HFO transition accelerates. Nuclear expansion EPC analysis produces a formal capacity announcement with DOE backing. Spokane expansion fully absorbed by TSMC/Intel demand. Analysts revise targets above $90. The stock breaks to new highs on multiple expansion toward 35x on a well-supported $3.50+ FY2027 EPS.
Base Case
~$73–82Solstice delivers FY2026 guidance — revenue ~$4.0B, EBITDA ~$1.0B, EPS ~$2.60. Margin recovery is gradual and Q1 comes in at the low end of guidance. Analysts maintain current PTs. Stock consolidates as investors wait for evidence of the nuclear expansion and aftermarket ramp. Fairly valued at ~30x forward earnings for a business with genuine secular tailwinds but limited near-term earnings growth.
Bear Case
~$55–65Q1 2026 margins disappoint — EBITDA below 23%, suggesting the HFO headwind is structural. TSA cost rolloff delayed. Management reduces 2026 EBITDA guidance. Simultaneously, semiconductor capex softens. The nuclear EPC study returns unfavorable economics and is deferred. De-rates from 30x to 22–24x forward earnings. At $2.60 EPS and 22x, stock trades near $57.
Key risks
01
HFO margin headwind — transitory or structural?
Management guided ~25% EBITDA margin recovery in 2026 as the HFO aftermarket builds. Q4 2025 EBITDA margin was 19.1% (mgmt adjusted). Q1 2026 on May 6 is the first real test. If margins print below 22%, the recovery narrative breaks and the stock re-rates.
02
HFO patent cliff — mid-2030s overhang
Composition-of-matter patents on core HFO molecules begin expiring mid-2030s. Chinese and Indian fluorochemical producers are building capability. Application patents extend to 2040s but the long-term pricing power depends on this protection holding and next-generation refrigerant development succeeding.
03
Metropolis Works operational reliability
The 66-year-old UF6 facility is the only US plant. Any operational incident, safety event, or NRC compliance issue could halt the nuclear business, which carries above-average EBITDA margins and is the most valued sub-segment on a per-dollar basis.
04
Semiconductor demand cyclicality
Electronic materials revenue is directly tied to leading-edge semiconductor capex. The Spokane expansion adds fixed cost leverage just as the cycle is at a peak. A traditional memory/logic inventory correction could hit ESM segment margins sharply and create utilization headwinds.
05
Spin-off execution — TSA costs and IT transition
Transition service agreements with Honeywell cost ~$30M in 2026, front-half weighted. IT and back-office separation runs through 2026. Any stumble adds costs or delays the standalone margin baseline. FY2026 is the first real credibility-building test for the standalone company.
Live data source: All market data, financial statements, analyst estimates, and comparable company data fetched on page load from Financial Modeling Prep (FMP) via secure Netlify Function proxy. API key is stored in Netlify environment variables and never exposed to the browser. Static sections (thesis, risks, scenarios, segment descriptions) are updated manually after each earnings quarter.
This memo was prepared by Claude Research (Anthropic AI) for Fitzgerald Investment Management Company. Internal use only. Not investment advice. Not for distribution.